A LinkedIn post from Insight Partners highlights portfolio company Proscia’s efforts to modernize pathology through digital workflows and embedded AI. The post cites comments from Cofounder and CEO David West, who is portrayed as aiming to bridge the gap between traditional pathology practices and contemporary software-driven approaches.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to the post, Proscia’s technology is designed to help pathology labs move beyond conventional microscope-based work to deliver faster, more precise insights for patient care and drug development. The emphasis on AI integration suggests a strategy focused on improving diagnostic speed and accuracy, which could enhance the company’s value proposition to healthcare providers and biopharma clients.
The post notes that in July 2025 Proscia was on track to diagnose 32,000 patients per day, which it describes as a 400% year-over-year increase. This level of volume growth, if sustainable, points to rapid adoption and potential scaling of recurring software and platform usage, factors that investors often view as supportive of long-term revenue expansion.
West is described as targeting 50 million patients diagnosed annually over the next five years, implying continued aggressive scaling ambitions. For investors, this growth trajectory, if achieved, could reinforce Proscia’s position within digital pathology and AI-enabled diagnostics, potentially strengthening Insight Partners’ exposure to healthcare technology and data-driven clinical workflows.